Compare Ginkgo Bioworks Holdings Inc (DNA) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Manhattan Associates Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Manhattan Associates Inc trades at $204.89 (market cap $12.06B). The key difference: Manhattan Associates Inc is far larger — about 15.8× Ginkgo Bioworks Holdings Inc's market cap, and Manhattan Associates Inc is more actively traded (376,150 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Manhattan Associates Inc for 12 Days on average.
| DNA | MANH | |
|---|---|---|
Market Cap | $763.64M | $12.06B |
Volume | 3,204,177 | 376,150 |
Sector | Health | Technology |
52-Week High | $15.83 | $223.76 |
52-Week Low | $5.48 | $120.88 |
Typical Hold Time | 7 Days | 12 Days |
Enterprise Value | $865.59M | $11.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
MANH trades at $204.89, up 1.38% on the day, with a bullish technical trend and strong profitability metrics including a 96.38% ROE and 18.67% net income margin. The stock has consistently beaten earnings estimates in recent quarters, though high valuation ratios like a P/E of 59.26 suggest premium pricing. Recent news includes a mix of positive product launches and ongoing legal investigations into fiduciary duties.
The outlook is cautiously optimistic, supported by analyst consensus and solid fundamentals, but risks include the high valuation, potential legal overhangs, and a projected decline in net income for 2026. Upside potential exists toward the $210.50 consensus target if execution remains strong.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
